Facebook
Twitter
Telegram
Report an ErrorArcus Biosciences Balance Sheet 2011-2024 | RCUS
Annual Balance Sheet Arcus Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6 M | -86 M | -31 M | -158 M | -57.9 M | -71.1 M | -98.4 M | -65.2 M | - | - | - | - | - |
Long Term Debt |
110 M | 117 M | 117 M | 15.2 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
11 M | 3 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 16.6 M | 23 M | 23.9 M | 4.7 M | - | - | - | - | - |
Total Current Liabilities |
184 M | 193 M | 166 M | 122 M | 22.7 M | 16.9 M | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 39.3 M | 40 M | 36.6 M | 10.2 M | - | - | - | - | - |
Deferred Revenue |
91 M | 97 M | 102 M | 74.6 M | 7 M | 6.25 M | 5 M | - | - | - | - | - | - |
Retained Earnings |
-849 M | -542 M | -275 M | - | -205 M | -123 M | -73.2 M | -20.2 M | - | - | - | - | - |
Total Assets |
1.1 B | 1.34 B | 1.59 B | 772 M | 203 M | 275 M | 190 M | 110 M | - | - | - | - | - |
Cash and Cash Equivalents |
127 M | 206 M | 148 M | 173 M | 57.9 M | 71.1 M | - | - | - | - | - | - | - |
Book Value |
1.1 B | 1.34 B | 1.59 B | 772 M | 164 M | 235 M | 154 M | 99.5 M | - | - | - | - | - |
Total Shareholders Equity |
462 M | 657 M | 842 M | 502 M | 164 M | 235 M | -72.3 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Arcus Biosciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | 119 M | - | 115 M | 117 M | 48.9 M | 49.7 M | 14.7 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | 695 M | - | 747 M | 750 M | 297 M | 294 M | 270 M | 270 M | 270 M | 270 M | 270 M | 39.3 M | 39.3 M | 39.3 M | 39.3 M | 40 M | 40 M | 40 M | 40 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
124 M | 91 M | 103 M | 103 M | 97 M | 97 M | 103 M | - | 89.3 M | 102 M | 74.3 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 7 M | 7 M | 7 M | 7 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M | 5 M | 5 M | 5 M | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-853 M | -849 M | -768 M | -697 M | -622 M | -542 M | -475 M | - | -343 M | -275 M | -555 M | -477 M | -401 M | -328 M | -328 M | -328 M | -328 M | -205 M | -205 M | -205 M | -205 M | -123 M | -123 M | -123 M | -123 M | -73.2 M | -73.2 M | -73.2 M | -73.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.29 B | 1.1 B | 1.19 B | 1.22 B | 1.25 B | 1.34 B | 1.39 B | - | 1.54 B | 1.59 B | 839 M | 899 M | 935 M | 772 M | 772 M | 772 M | 772 M | 203 M | 203 M | 203 M | 203 M | 275 M | 275 M | 275 M | 275 M | 190 M | 190 M | 190 M | 190 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
185 M | 127 M | 184 M | 230 M | 238 M | 206 M | 218 M | 273 M | 549 M | 148 M | 179 M | 320 M | 390 M | 173 M | 173 M | 173 M | 173 M | 57.9 M | 57.9 M | 57.9 M | 57.9 M | 71.1 M | 71.1 M | 71.1 M | 71.1 M | 98.4 M | 98.4 M | 98.4 M | 98.4 M | 65.2 M | - | - | - | 46.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | - | 1.34 B | 699 M | - | 797 M | 841 M | 543 M | 605 M | 665 M | 502 M | 502 M | 502 M | 502 M | 164 M | 164 M | 164 M | 164 M | 235 M | 235 M | 235 M | 235 M | 154 M | 154 M | 154 M | 154 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
707 M | 462 M | 520 M | 566 M | 600 M | 657 M | 699 M | 747 M | 797 M | 841 M | 543 M | 605 M | 665 M | 502 M | 502 M | 502 M | 502 M | 164 M | 164 M | 164 M | 164 M | 235 M | 235 M | 235 M | 235 M | -72.3 M | -72.3 M | -72.3 M | -72.3 M | -20 M | - | - | - | -2.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency